Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Chartwell Investment Partners LLC

Chartwell Investment Partners LLC grew its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 58.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 35,800 shares of the medical equipment provider's stock after acquiring an additional 13,257 shares during the quarter. Chartwell Investment Partners LLC owned about 0.05% of Lantheus worth $3,929,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in LNTH. Signaturefd LLC lifted its position in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after buying an additional 92 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 208 shares during the period. UMB Bank n.a. grew its holdings in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after purchasing an additional 126 shares during the period. Kathleen S. Wright Associates Inc. acquired a new stake in Lantheus during the third quarter worth about $51,000. Finally, Nkcfo LLC purchased a new stake in shares of Lantheus in the 2nd quarter valued at approximately $47,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of NASDAQ:LNTH traded up $1.07 during trading on Tuesday, hitting $85.15. The company's stock had a trading volume of 1,725,883 shares, compared to its average volume of 1,002,664. The company has a market capitalization of $5.92 billion, a PE ratio of 13.99 and a beta of 0.51. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The business has a 50 day moving average price of $106.89 and a two-hundred day moving average price of $96.26.

Analysts Set New Price Targets

LNTH has been the topic of a number of recent analyst reports. B. Riley upped their price objective on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. JMP Securities decreased their price target on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research note on Thursday, November 7th. Redburn Atlantic started coverage on Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective for the company. Truist Financial reaffirmed a "buy" rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research report on Friday. Finally, StockNews.com upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Friday. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, Lantheus has an average rating of "Moderate Buy" and an average target price of $122.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.